Medesis Pharma S.A.

ALMDP

FR0010844464

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 08:19:25 2024-04-26 am EDT			5-day change	1st Jan Change
1.4 ^EUR	-2.10%		-10.83%	+61.29%

2023	Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	MEDESIS : Invest Securities confirms its recommendation	CF

Medesis Pharma SA announced that it has received €0.04 million in funding

October 25, 2015

On October 26, 2015, Medesis Pharma SA closed the transaction. The company has received €40,000 in funding.

Latest news about Medesis Pharma S.A.

Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-27	CI
MEDESIS : Invest Securities confirms its recommendation	23-10-06	CF
Medesis Pharma: selected for the Prix Galien USA	23-08-04	CF
MEDESIS : Invest Securities maintains its recommendation	23-07-12	CF
MEDESIS : Invest Securities confirms its recommendation	23-07-07	CF
Global markets live: Gamestop, Lucid, Meta Platforms, Vodafone, Nestlé...	23-06-08
Global markets live: Shell, Netflix, Nike, Ocado, Tesla...	23-03-31
Global markets live: Blackberry, Meta Platforms, Rivian, GM...	23-03-07
Medesis Pharma Soars 16% On New Grant For Investigational Huntington's Disease Drug	22-07-20	MT
Medesis Pharma Up 65% After Asking Funds For Nuclear Contamination Drugs	22-04-05	MT
Medesis Pharma Publishes an Information Note on the Three Future Drugs in Development for the Protection of Large Populations Contaminated After A Civil or Military Nuclear Accident	22-04-05	CI
Medesis Pharma Wins COVID-19 Drug Trial Approval In Brazil	21-11-22	MT
Global markets live: Ford, Walmart, Apple, Volkswagen, Tesla...	21-09-02
Global markets live: Nvidia, Microsoft, Dell, Apple, Uber...	21-08-27
Medesis Pharma S.A.(ENXTPA:ALMDP) added to Next Biotech Index	21-02-15	CI
Medesis Pharma S.A. has completed an IPO in the amount of €7.350317 million.	21-02-09	CI
Medesis Pharma S.A. has filed an IPO in the amount of €7.350317 million.	21-01-26	CI
Medesis Pharma SA announced that it has received €0.04 million in funding	15-10-25	CI
Medesis Pharma SA announced that it expects to receive €1 million in funding.	15-09-17	CI

Medesis Pharma S.A. is specialized in the research and development, based on a breakthrough technology (AONYS®) for the delivery of therapeutic molecules, of drugs to treat diseases for which there is no effective treatment. The company's portfolio includes a drug candidate used to optimize cancer radiotherapy, 2 drug candidates used in the treatment of neurodegenerative diseases (Alzheimer's disease and Huntington's disease) and 2 drug candidates used in the treatment of radioactive contamination following a civil or military nuclear accident (Plutonium decorporation and cesium decorporation).

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDESIS PHARMA S.A.	+61.29%	6.62M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B